Plerixafor powder is used for injection. It is primarily used in conjunction with other medications to mobilise stem cells in patients undergoing autologous hematopoietic stem cell transplantation (HSCT) for non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). This substance functions by blocking the CXCR4 chemokine receptor, which promotes the circulatory release of stem cells from the bone marrow. Plerixafor powder enhances the quantity of stem cells that are available for collecting and transplantation by improving stem cell mobilisation. It is normally reconstituted with a sterile diluent to create a solution that is subsequently injected subcutaneously or intravenously when it is recommended.